| Literature DB >> 27190572 |
Xiaochun Duan1, Zunjia Wen2, Haitao Shen2, Meifen Shen2, Gang Chen2.
Abstract
Hemorrhagic stroke is a common and severe neurological disorder and is associated with high rates of mortality and morbidity, especially for intracerebral hemorrhage (ICH). Increasing evidence demonstrates that oxidative stress responses participate in the pathophysiological processes of secondary brain injury (SBI) following ICH. The mechanisms involved in interoperable systems include endoplasmic reticulum (ER) stress, neuronal apoptosis and necrosis, inflammation, and autophagy. In this review, we summarized some promising advances in the field of oxidative stress and ICH, including contained animal and human investigations. We also discussed the role of oxidative stress, systemic oxidative stress responses, and some research of potential therapeutic options aimed at reducing oxidative stress to protect the neuronal function after ICH, focusing on the challenges of translation between preclinical and clinical studies, and potential post-ICH antioxidative therapeutic approaches.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27190572 PMCID: PMC4848452 DOI: 10.1155/2016/1203285
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Schematic representation of major intracellular pathway in the role of reactive oxygen species radicals in hemorrhagic stroke. ROS: Reactive oxygen species; RNS: reactive nitrogen species; ICH: intracerebral hemorrhage; ER stress: endoplasmic reticulum stress; BBB: blood brain barrier.
Human biomarkers and oxidative stress after ICH.
| Biomarkers | Sample | Methods | Value | References |
|---|---|---|---|---|
|
8-iso-Prostaglandin F2 | Urinary | Liquid chromatography, tandem mass spectrometry | Independent biomarker of prediction of the risk for incident stroke | [ |
|
| ||||
|
8-iso-Prostaglandin F2 | Plasma | Enzyme-linked immunosorbent assay | Disease severity and clinical outcome after acute ICH associated with concentration | [ |
|
| ||||
| 8-OHdG | Plasma | HPLC-electrochemical detector | Level associated with 30-day outcome after ICH | [ |
|
| ||||
| Bilirubin | Plasma | Reflectance spectrophotometry | Serum bilirubin levels were significantly elevated in the early phases in hemorrhagic stroke | [ |
|
| ||||
| Vitamin C, uric acid (UA), vitamin E, ubiquinol-10 | Plasma | HPLC-electrochemical detector | Lower plasma levels of UA and higher plasma levels of others correlated with the severity of the neurological impairment after ICH | [ |
|
| ||||
| ROOH | Plasma | HPLC-electrochemical detector | Predictor of poor clinical outcome in sICH survivors | [ |
|
| ||||
| TAC, TOS | Plasma | Spectrophotometrically | TOS levels increased and TAC levels decreased in acute hemorrhagic stroke | [ |
MDA, myeloperoxidase; erythrocyte glutathione peroxidase; 8-OHdG, leukocyte 8-hydroxy-2′-deoxyguanosine; HPLC, high-performance liquid chromatography; TAC, total antioxidant capacity; TOS, total oxidant status.
The development for antioxidative treatment of ICH.
| Drug name | Administration | Probable mechanism of action or drug targeting | Preclinical or clinical | References |
|---|---|---|---|---|
| PQQ | Pretreated with 10 mg/kg | Exhibited increased ratio of Bcl-2/Bax, alleviative to activated caspase-3 | Rat model of ICH | [ |
|
| ||||
| Melatonin | 150 mg/kg/d, ip; 5 mg/kg/12 h, ip; 15 or 150 mg/kg, ip | Attenuated inflammatory response (IL-1 | Rat model of SAH or ICH | [ |
|
| ||||
| Sulforaphane | 5 mg/kg, ip | Activated Nrf2 in modulating microglia function and hematoma clearance via inducing antioxidative defense components | Rat and mice model of ICH | [ |
|
| ||||
| Sesamin | 30 nmol, icv | Sesamin prevented ICH-induced increase of microglial cells in the perihematomal area, accompanied by the activated p44/42 MAPK pathway | Rat model of ICH | [ |
|
| ||||
| FeTPPS | 30 mg/kg, ip | ONOO− decomposition catalyst; prevented activation of MMP-9 and Hb-induced neurovascular injuries | Rat model of ICH | [ |
|
| ||||
| Deferoxamine | 100 mg/kg, ip | Reduces neuronal death and neurological deficits after ICH in aged rats | Rat model of ICH | [ |
|
| ||||
| Edaravone | 6 mg/kg, SC | Attenuated ICH-induced brain edema, neurologic deficits, and oxidative injury (apurinic/apyrimidinic abasic sites and 8-hydroxyl-2′-deoxyguanosine) | Rat model of ICH | [ |
|
| ||||
| Edaravone | 10 mg/kg, SC | Improved cerebral metabolism around the hematoma by attenuating apoptotic cell death after ICH | Rat model of ICH | [ |
|
| ||||
| Hydrogen gas | Inhaled, 2.9% | Reduces damage to the blood brain barrier following ICH and improves SBI | Mice model of ICH | [ |
|
| ||||
| Rosiglitazone | 0.5 mg, infused into the hematoma regions | A remarkable decrease in perihematomal levels of PPAR | Rabbits model of ICH | [ |
|
| ||||
| Minocycline | 45 mg/kg, ip | Reduces iron accumulation and inhibits microglia activation contributing to brain damage after ICH via suppressing MMP-9 | Rat model of ICH | [ |
|
| ||||
| Atorvastatin | 2, 5, and 10 mg/kg, orally | Decreasing the brain injury and protecting neurons in ICH involving suppression of TNF- | Rat model of ICH | [ |
PQQ, pyrroloquinoline quinine; MMP-9, matrix metallopeptidase 9; TLR4, Toll-like receptor 4; iNOS, inducible nitric oxide synthase; MyD88, myeloid differentiation factor 88; ip, intraperitoneal injection; icv, intracerebroventricular injection; SC, subcutaneous injection.
Potential medications that target oxidative stress in patients after hemorrhagic stroke.
| Drug name | Clinical trials | Different types of intracerebral hemorrhage | Action mechanism | Outcome | References |
|---|---|---|---|---|---|
| NXY-059 |
| ICH | Free radical-trapping agent | No benefit | [ |
|
| |||||
| Deferoxamine mesylate |
| ICH | Iron-chelator | Phase II clinical trial | [ |
|
| |||||
| Hydrogen-rich fluid |
| SAH | Delayed cerebral ischemia and cerebral vasospasm | Ongoing | [ |
|
| |||||
| Edaravone | — | SAH | Free radical scavenger | Preliminary | [ |
|
| |||||
| Simvastatin |
| SAH | Lipid-lowering therapy | No benefit | [ |
|
| |||||
| Lipid-lowering medication |
| ICH | Lipid-lowering therapy | No benefit | [ |
|
| |||||
| Statin |
| SAH | Lipid-lowering therapy | No benefit | [ |
ICH, intracranial hemorrhage; SAH, subarachnoid hemorrhage.